FluoGuide obtains patent protection for FG001 in Australia

| 30 november, 2020 | 0 kommentarer

Copenhagen, Denmark, 30 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that the Company has successfully secured patent protection for its lead clinical asset FG001 in Australia. The protection is granted by the Australian Commissioner of Patents. The patent number is 2015317444 and will remain valid until September 2035.

FG001 is designed to allow surgeons to clearly delignate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology and is currently used in a phase I/II clinical trial in guiding surgery of high grade glioma.

The Australian Commissioner of Patents has granted and registered FluoGuide’s patent application for its lead asset FG001. The patent (no. 2015317444) with title “uPAR targeting peptide for use in peroperative optical imaging of invasive cancer” will remain valid until September 2035. The patent has previously been issued in the USA and Europe and with this patent, FluoGuide continues to expand it’s intellectual property portfolio for its lead asset.

For further information:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
[email protected]

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is undertaking a proof-of-concept clinical trial (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma including glioblastoma.

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.

Kategori: Marknadsnyheter

Om skribenten ()

Tanalys är en sajt för investerare som med teknisk analys vill förbättra sin trading. Tanalys erbjuder teknisk analys från flera ledande analytiker, samt nyheter och utbildningar.

Lämna ett svar

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *